{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:23:16Z","timestamp":1791912196321,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cefuroxime allergy may present as a delayed-type reaction or as an immunoglobulin (Ig)E-mediated immediate-type anaphylactic reaction. The basophil activation test (BAT) is a diagnostic tool for cefuroxime-induced immediate-type reactions, whereas the lymphocyte transformation test (LTT) is typically applied in delayed-type drug allergy. This study aimed to compare the results of the BAT and LTT in 15 patients with cefuroxime-induced anaphylactic reactions considered as confirmed. The pharmacoepidemiological part aimed to analyze spontaneous reports of cefuroxime-associated anaphylactic reactions in the European adverse drug reaction database (EudraVigilance).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In EudraVigilance, 668 reports of cefuroxime-associated anaphylactic reactions for the European Economic Area (EEA) between 2010 and 2023 were analyzed, with 182 (27.2%) of these reports originating from Germany. The BAT and the LTT were performed according to standard protocols. Except for one patient, all BAT were performed prior to the skin tests, whereas all LTT were performed thereafter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Almost all reports were classified as serious (EEA, 99.3%; Germany, 98.9%). In 60.8% (EEA) and 66.9% (Germany) of reports with respective information, the reaction occurred after intravenous administration. BAT was performed in 12 of 15 patients (3\/12 positive; sensitivity 25%), while LTT was performed in all 15 patients (7\/15 positive; sensitivity 46.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our analysis highlights the importance of cefuroxime-associated anaphylactic reactions, as almost all of the spontaneous reports were classified as serious. Neither a negative BAT nor LTT can rule out a sensitization in cefuroxime-induced anaphylactic reactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1532775","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:16:58Z","timestamp":1743121018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions"],"prefix":"10.3389","volume":"6","author":[{"given":"Andreas","family":"Gl\u00e4ssner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dubrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Wurpts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Deck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Weindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar A.","family":"Heubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir S.","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40629-019-0100-8","article-title":"Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics","volume":"28","author":"Wurpts","year":"2019","journal-title":"Allergo J Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra993637","article-title":"Cephalosporin allergy","volume":"345","author":"Kelkar","year":"2001","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5414\/ALX02422E","article-title":"Guideline for allergological diagnosis of drug hypersensitivity reactions","volume":"7","author":"Brockow","year":"2023","journal-title":"Allergologie Select"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1009437","DOI":"10.3389\/falgy.2022.1009437","article-title":"Towards an FDA-cleared basophil activation test","volume":"3","author":"Alpan","year":"2023","journal-title":"Front Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"113050","DOI":"10.1016\/j.jim.2021.113050","article-title":"Basophil and mast cell activation tests by flow cytometry in immediate drug hypersensitivity: diagnosis and beyond","volume":"495","author":"Elst","year":"2021","journal-title":"J Immunol Methods"},{"key":"B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40521-023-00345-6","article-title":"Optimising the utility of in vitro tests for the diagnosis of drug allergy: insights from a clinical perspective","volume":"10","author":"Sabat\u00e9-Bresc\u00f3","year":"2023","journal-title":"Curr Treat Options Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2386654","DOI":"10.1155\/2022\/2386654","article-title":"In vitro assays for diagnosis of drug-induced nonsevere exanthemas: a systematic review and meta-analysis","volume":"2022","author":"Drygala","year":"2022","journal-title":"J Immunol Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/cea.14253","article-title":"In vitro detection of T cell sensitization by interferon\u2013\u03b3 secretion in immediate-type drug allergy","volume":"53","author":"Gl\u00e4ssner","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.anai.2022.06.014","article-title":"Lymphocyte transformation test for drug allergy detection: when does it work?","volume":"129","author":"Gl\u00e4ssner","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1034\/j.1398-9995.2001.000115.x","article-title":"In vitro T-cell responses to \u03b2-lactam drugs in immediate and nonimmediate allergic reactions","volume":"56","author":"Luque","year":"2008","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"113072","DOI":"10.1016\/j.jim.2021.113072","article-title":"Future perspectives on in vitro diagnosis of drug allergy by the lymphocyte transformation test","volume":"495","author":"Fatangare","year":"2021","journal-title":"J Immunol Methods"},{"key":"B13","doi-asserted-by":"publisher","first-page":"113098","DOI":"10.1016\/j.jim.2021.113098","article-title":"Lymphocyte transformation test and cytokine detection assays: determination of read out parameters for delayed-type drug hypersensitivity reactions","volume":"496","author":"Srinoulprasert","year":"2021","journal-title":"J Immunol Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B15","article-title":"Guideline on good pharmacovigilance practices (GVP). Annex I - definitions (Rev 4)","year":"2017"},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3238\/arztebl.2018.0393","article-title":"Frequent adverse drug reactions, and medication groups under suspicion","volume":"115","author":"Dubrall","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"B17","article-title":"EudraVigilance","year":""},{"key":"B18","article-title":"MedDRA","year":""},{"key":"B19","article-title":"European Medicines Agency. eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) data-entry tool (EVWEB) user manual (2024)","year":""},{"key":"B20","article-title":"PharMaAnalyst","year":""},{"key":"B21","article-title":"Statista","year":""},{"key":"B22","article-title":"Activities MDfR","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"309","author":"Ring","year":"1977","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2024.11.006","article-title":"Analysis of differential gene expression of PBMC for the in vitro detection of drug sensitization","author":"Gl\u00e4ssner","year":"2025","journal-title":"Allergol Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"113036","DOI":"10.1016\/j.jim.2021.113036","article-title":"Lymphocyte transformation test: history and current approaches","volume":"493","author":"Sachs","year":"2021","journal-title":"J Immunol Meth"},{"key":"B26","unstructured":"B\u00dcHLMANN Laboratories AG. Flow CAST (2023)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40264-017-0534-1","article-title":"Patient reporting in the EU: analysis of EudraVigilance data","volume":"40","author":"Banovac","year":"2017","journal-title":"Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40264-023-01359-4","article-title":"French pharmacovigilance network. Impact of COVID-19 vaccination on spontaneous pharmacovigilance reporting in France","volume":"46","author":"De Germay","year":"2023","journal-title":"Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1512875","DOI":"10.3389\/falgy.2024.1512875","article-title":"Determining the role of basophil activation testing in reported type 1 allergy to beta-lactam antibiotics","volume":"5","author":"Reitmajer","year":"2024","journal-title":"Front Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1398-9995.2009.01985.x","article-title":"Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-[gamma] in patients with delayed-type drug hypersensitivity","volume":"64","author":"Lochmatter","year":"2009","journal-title":"Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1532775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:17:02Z","timestamp":1743121022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1532775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":31,"alternative-id":["10.3389\/falgy.2025.1532775"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1532775","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1532775"}}